Hong Kong (HSI) Drug Retail Industry Analysis

Industry Valuation and Performance

Has the Hong Kong Drug Retail Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 15 Jul 2026	HK$190.6b	HK$142.9b	HK$8.7b	30.2x	21.9x	1.3x
Fri, 12 Jun 2026	HK$198.7b	HK$143.0b	HK$8.7b	33.4x	22.8x	1.4x
Sun, 10 May 2026	HK$248.3b	HK$140.9b	HK$8.7b	43.8x	28.7x	1.8x
Tue, 07 Apr 2026	HK$263.3b	HK$139.4b	HK$8.6b	46.6x	30.7x	1.9x
Thu, 05 Mar 2026	HK$276.3b	HK$129.5b	HK$6.9b	37.7x	39.8x	2.1x
Sat, 31 Jan 2026	HK$346.5b	HK$128.5b	HK$6.9b	48.6x	50.4x	2.7x
Mon, 29 Dec 2025	HK$308.4b	HK$126.9b	HK$6.8b	38.8x	45.4x	2.4x
Wed, 26 Nov 2025	HK$334.1b	HK$122.9b	HK$6.2b	61.3x	54.1x	2.7x
Fri, 24 Oct 2025	HK$334.8b	HK$122.1b	HK$6.1b	61.2x	54.5x	2.7x
Sun, 21 Sep 2025	HK$382.4b	HK$122.3b	HK$6.1b	68.4x	62.2x	3.1x
Tue, 19 Aug 2025	HK$348.7b	HK$122.5b	HK$5.1b	57x	68.4x	2.8x
Thu, 17 Jul 2025	HK$252.0b	HK$115.4b	HK$4.5b	47.5x	55.9x	2.2x
Sat, 14 Jun 2025	HK$230.0b	HK$115.3b	HK$4.5b	47.4x	51.1x	2x
Mon, 12 May 2025	HK$223.4b	HK$111.0b	HK$4.2b	61.8x	53.4x	2x
Wed, 09 Apr 2025	HK$179.8b	HK$109.3b	HK$4.1b	51.6x	43.6x	1.6x
Fri, 07 Mar 2025	HK$245.1b	HK$104.2b	HK$3.6b	58.6x	67.9x	2.4x
Sun, 02 Feb 2025	HK$178.0b	HK$104.4b	HK$3.6b	40.6x	49.3x	1.7x
Tue, 31 Dec 2024	HK$156.1b	HK$103.3b	HK$3.6b	37.3x	43.6x	1.5x
Thu, 28 Nov 2024	HK$169.4b	HK$104.4b	HK$3.6b	38.6x	46.9x	1.6x
Sat, 26 Oct 2024	HK$173.9b	HK$104.5b	HK$3.3b	49x	52.4x	1.7x
Mon, 23 Sep 2024	HK$147.5b	HK$105.9b	HK$3.4b	39.8x	43.9x	1.4x
Wed, 21 Aug 2024	HK$135.9b	HK$104.7b	HK$3.0b	37.4x	45.5x	1.3x
Fri, 19 Jul 2024	HK$141.3b	HK$102.0b	HK$2.4b	43.4x	59.1x	1.4x
Sun, 16 Jun 2024	HK$154.4b	HK$102.1b	HK$2.4b	46.6x	64.6x	1.5x
Tue, 14 May 2024	HK$168.3b	HK$103.7b	HK$2.3b	50.1x	72.4x	1.6x
Thu, 11 Apr 2024	HK$148.8b	HK$104.0b	HK$2.3b	44.2x	63.8x	1.4x
Sat, 09 Mar 2024	HK$162.1b	HK$105.1b	-HK$1,456,481,797.74	53.7x	-111.3x	1.5x
Mon, 05 Feb 2024	HK$148.4b	HK$105.1b	-HK$1,456,303,487.00	48.1x	-101.9x	1.4x
Wed, 03 Jan 2024	HK$205.7b	HK$105.8b	-HK$1,465,904,217.00	63.9x	-140.3x	1.9x
Fri, 01 Dec 2023	HK$206.6b	HK$105.7b	-HK$1,465,280,878.00	65.2x	-141x	2x
Sun, 29 Oct 2023	HK$205.0b	HK$101.7b	-HK$1,734,606,974.00	86x	-118.2x	2x
Tue, 26 Sep 2023	HK$227.9b	HK$102.2b	-HK$1,672,657,299.00	101.3x	-136.2x	2.2x
Thu, 24 Aug 2023	HK$221.0b	HK$102.5b	-HK$2,687,970,921.00	72.6x	-82.2x	2.2x
Sat, 22 Jul 2023	HK$270.4b	HK$96.3b	-HK$4,178,456,975.00	117.6x	-64.7x	2.8x

Current Industry PE

Investors are pessimistic on the Hong Kong Drug Retail industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The industry is trading at a PE ratio of 21.9x which is lower than its 3-year average PE of 98.1x.

The 3-year average PS ratio of 2.0x is higher than the industry's current PS ratio of 1.3x.

Past Earnings Growth

Total earnings for the Drug Retail industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 14% per year.
This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.

Industry Comparison

How does Hong Kong Drug Retail compare with similar industries?


HK Market	2.14%
Consumer Staples	1.41%
Food and Staples Retail	2.73%
Drug Retail	1.97%
Big Box Super Stores	5.54%
Food Retail	3.94%
Food Distributors	-0.81%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

	Company	Last Price	7D	1Y	Valuation
	6618 JD Health International	HK$37.52	0.5% +HK$638.3m	-17.8%	PE19.2x
	6086 Fangzhou	HK$0.84	12.0% +HK$124.7m	-78.8%	PE84.9x

Company

Last Price

Valuation

6618 JD Health International

HK$37.52

0.5%
+HK$638.3m

-17.8%

PE19.2x

6086 Fangzhou

HK$0.84

12.0%
+HK$124.7m

-78.8%

PE84.9x

Fangzhou Inc. Showcases Ai-Powered Chronic Disease Management Solution with Tencent Health At Tencent Cloud Conference

Fangzhou Inc. attended the 2026 Tencent Cloud AI Industry Applications Summit in Beijing, where it showcased its “AI + Chronic Disease Services” digital solution developed in collaboration with Tencent Health. Fangzhou demonstrated how AI is being integrated into chronic disease management through its “AI + H2H (Hospital-to-Home)” smart healthcare ecosystem. Built on its proprietary XingShi Large Language Model (“XS LLM”), Fangzhou’s AI + Chronic Disease Services solution is designed to enhance care delivery, improve patient outcomes, and expand access to professional healthcare services. Fangzhou’s AI-powered approach focuses on supporting both patients and physicians across the chronic disease management journey. For patients, AI functionality can provide personalized health management recommendations, risk monitoring, and behavioral interventions, helping make long-term care more accessible and effective. For physicians, AI-powered assistants help reduce administrative workloads and streamline routine tasks, enabling doctors to devote more time to diagnosis, treatment, and patient engagement. Fangzhou noted that the integration of AI into chronic disease services is helping to transform healthcare beyond one-time consultations toward continuous, full-cycle health management. By combining advanced technology with long-term patient support, the Company aims to improve service efficiency while strengthening trust and engagement between patients and healthcare providers. The summit also highlighted the ongoing collaboration between Fangzhou and Tencent Health. Since expanding their strategic partnership in November 2025, the two companies have worked together to combine Fangzhou’s healthcare expertise and chronic disease management capabilities with Tencent Health’s technology infrastructure, supporting the development and deployment of AI applications across a broad range of healthcare use cases. Tencent Health’s technology platform provides Fangzhou with access to scalable computing resources and end-to-end model development tools that support the continuous optimization of its AI capabilities. The solution also utilizes Tencent Health’s vector database technology, enabling rapid retrieval from large-scale medical knowledge repositories and improving the accuracy and reliability of AI-generated content. Fangzhou will continue to prioritize technological innovation and ecosystem collaboration as key pillars of its long-term growth strategy. By working closely with Tencent Health and other industry partners, the Company aims to further expand the reach of AI-powered chronic disease services, helping deliver more efficient, personalized, and accessible healthcare support to patients while contributing to the digital transformation of China’s healthcare sector.

Hong Kong (HSI) Drug Retail Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

Ping An Healthcare and Technology Company Limited to Report First Half, 2026 Results on Aug 18, 2026

Investor sentiment improves as stock rises 40%

Alibaba Health Information Technology Limited, Annual General Meeting, Aug 07, 2026

Should You Investigate JD Health International Inc. (HKG:6618) At HK$36.10?

Fangzhou Inc. Showcases Ai-Powered Chronic Disease Management Solution with Tencent Health At Tencent Cloud Conference

Dingdang Health Technology Group Ltd., Annual General Meeting, Jun 23, 2026